Bio-Path Holdings Inc.

+$0.05 (+0.8%)
Closing price February 29, 2024
Bio-Path stock has taken a beating in the past five years. Investors obviously aren’t happy about this, and the way that management and the board of directors has handled it has been clumsy.
Like all developmental drug companies, Bio-Path is betting on the success of its drug candidates. Drugs that are in trials often fail, so investors need to gamble that one or more of its treatments...
What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of shareholder value? That's what happened to Bio-Path.